Rael David Strous: Influence Statistics

Rael David Strous

Rael David Strous

Mayanei Hayeshua Medical Center, HaRav Povarsky, 17, Bnei Brak, Israel | Psychiatry Department, Mayanei Hayeshua Medical Center, Bnei Brak, Israel | Sackler School of ...

Rael David Strous: Expert Impact

Concepts for which Rael David Strous has direct influence: Schizophrenia patients , Chronic schizophrenia , Rgs2 gene , Autistic disorder , Bipolar disorder , Postpartum ptsd , Postpartum depression .

Rael David Strous: KOL impact

Concepts related to the work of other authors for which for which Rael David Strous has influence: Bipolar disorder , Schizophrenia patients , Negative symptoms , Comt gene , Tardive dyskinesia , Neuroactive steroids , Medical students .

KOL Resume for Rael David Strous

Year
2021

Mayanei Hayeshua Medical Center, HaRav Povarsky, 17, Bnei Brak, Israel

2020

Department of Psychiatry, Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel

Maayenei Hayeshua Medical Center

2019

Maayenei Hayeshua Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

2018

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

2017

Beer Yaakov Mental Health Center, Beer Yaakov, Israel

2016

From the Beer Yaakov Mental Health Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; The PANSS Institute, New York; and the Clinical Psychology Doctoral Program, Long Island University, New York.

2014

Beer Yaakov-Ness Ziona Mental Health Center, Beer Yaakov, Israel Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

2013

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 69978

2012

Beer Yaakov Mental Health Center, Israel

2011

Tel Aviv University, Beer Yaakov Mental Health Center, Sackler Faculty of Medicine, 70350 Beer Yaakov, PO Box 1, Tel Aviv, Israel

2010

Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel

2009

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, and Beer Yaakov Mental Health Center, Beer Yaakov, Israel

2008

Department of Psychiatry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel

Beer Yaakov Mental Health Center, Sackler Faculty of Medicine, Tel Aviv University

2007

Department of Psychiatry, Beer Yaakov Mental Health Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

RD Strous is Director of the Inpatient Unit at the Beer Yaakov Mental Health Center and Senior Lecturer in Psychiatry at the Sackler School of Medicine, Tel Aviv University.

2006

Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel

2005

Beer Yaakov Mental Health Centre, Beer Yaakov, Israel

2004

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Research Unit, Ness Ziona Mental Health Center, Ness Ziona Mental Health Center, Ness Ziona, Laboratory of Clinical Biochemistry, Tel Aviv Sourasky Medical Center, Tel Aviv, Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, and Geha Mental Health Center, Petah-Tikva, and, Beer Yaakov Mental Health Center, Beer Yaakov, Israel

2003

*Beer Yaakov Mental Health Center, †Sackler Faculty of Medicine, Tel Aviv University, ‡Tirat Carmel Mental Health Center, §Geha Mental Health Center, Israel

Massachusetts Mental Health Center, Boston, MA,USA

Harvard Medical School, Department of Psychiatry, 74 Fenwood Road, Boston, MA 02115, USA

2002

Beer Yaakov Mental Health Center, Beer Yaakov (RS), Israel

Sackler School of Medicine, Tel Aviv University, Tel Aviv

2001

Beer Yaacov Mental Health Center, Beer Yaacov 70300, Israel; and

2000

Commonwealth Research Center, Massachusetts Mental Health Center, and the Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

1997

Department of Psychiatry, Hillside Hospital-Long Island Jewish Medical Center Glen Oaks, New York, USA

1996

Department of Psychiatry, Albert Einstein College of Medicine/Bronx Psychiatric Center, New York, USA.

Prominent publications by Rael David Strous

KOL-Index: 13570 . BACKGROUND: Substance dependence is more common among trauma-exposed individuals; however, most studies suggest that Posttraumatic Stress Disorder (PTSD) accounts for the link between trauma exposure (TE) and substance dependence. OBJECTIVES: This study examined associations between TE and substance dependence (alcohol, nicotine, and marijuana), and whether PTSD accounted for this ...
Known for Trauma Exposure | Ptsd Symptoms | Stress Disorder | Nicotine Dependence
KOL-Index: 12348 . Dopamine is a major neurotransmitter in the central nervous system, and its receptors are associated with a number of neuropathological disorders such as Parkinson's disease and schizophrenia. Although the precise pathophysiology of schizophrenia remains unknown, the dopaminergic hypothesis of the illness assumes that the illness results from excessive activity at dopamine synapses in the ...
Known for D3 Dopamine | Peripheral Marker | Messenger Receptors | Blood Lymphocytes
KOL-Index: 11856 . CONTEXT: Negative symptoms of schizophrenia are a prominent feature of the illness, and frequently remain refractory to treatment. Dehydroepiandrosterone (DHEA), along with its sulfated form, DHEA-S, is an important circulating neurosteroid with several vital neurophysiological functions, including the regulation of neuronal excitability and function. OBJECTIVE: Since the administration of ...
Known for Anxiety Symptoms | Dehydroepiandrosterone Dhea | Schizophrenic Patients | Neuronal Excitability
KOL-Index: 10946 . Substance use disorders, particularly those involving alcohol, marijuana, and cocaine, are highly prevalent among patients with schizophrenia and contribute markedly to its overall morbidity. Unfortunately, standard (typical) antipsychotic medications do not seem to reduce substance use in patients with schizophrenia and may even increase it. Recently, however, a few anecdotal case reports ...
Known for Schizoaffective Disorder | Substance Patients | Treatment Clozapine | Retrospective Studies
KOL-Index: 10201 . BACKGROUND: Alcohol and cannabis use disorders worsen the course of schizophrenia. While the typical antipsychotics are of limited value in controlling substance use in schizophrenic patients, previous studies suggest that the novel antipsychotic clozapine (CLOZ) may decrease their substance use. We describe a retrospective study of the effects of the novel antipsychotics risperidone ...
Known for Clozapine Risperidone | Cannabis Patients | Retrospective Studies | 1 Year
KOL-Index: 10065 . Patients with schizophrenia exhibit a decrease or loss of normal anatomical brain asymmetry that also extends to functional levels. We applied functional magnetic resonance imaging (fMRI) to investigate language lateralization in patients with schizophrenia during their first episode of illness, thus excluding effects of chronic illness and treatment. Brain regions activated during ...
Known for Language Lateralization | Patients Schizophrenia | Brain Regions | Functional Asymmetry
KOL-Index: 10055 . A variety of psychiatric illnesses, including schizophrenia and bipolar disorder, have been reported in patients with microdeletion on chromosome 22q11-a region which includes the catechol-O-methyltransferase (COMT) gene. The variety of psychiatric manifestations in patients with the 22q11 microdeletion and the role of COMT in the degradation of catecholamine neurotransmitters may thus ...
Known for Bipolar Disorder | Comt Gene | Schizophrenia Association | Psychiatric Diseases
KOL-Index: 9828 . Based on their metabolic inactivation of dopamine and norepinephrine, genes encoding the catechol-O-methyltransferase (COMT) enzyme are appropriate candidates to consider in the pathogenesis of schizophrenia. COMT enzyme activity is regulated by a common polymorphism causing substantial variations in enzymatic activity, and evidence for allelic or genotypic association with cognitive and ...
Known for Comt Polymorphism | Schizophrenia Association | Clinical Symptomatology | Metabolic Inactivation
KOL-Index: 9769 . Methylphenidate is considered by many to be the treatment of choice for attention deficit hyperactivity disorder (ADHD). Methylphenidate exerts its therapeutic effects through the dopaminergic, serotonergic and noradrenergic systems, however its effects on other neurophysiological systems, such as the neurosteroidal system, remain unknown. Dehydroepiandrosterone (DHEA) and its sulfate ...
Known for Hyperactivity Disorder | Attention Deficit | Treatment Methylphenidate | Plasma Levels
KOL-Index: 9685 . RGS2 (regulator of G-protein signaling 2) modulates dopamine receptor signal transduction. Functional variants in the gene may influence susceptibility to extrapyramidal symptoms (EPS) induced by antipsychotic drugs. To further investigate our previous report of association of the RGS2 gene with susceptibility to antipsychotic-induced EPS, we performed a replication study. EPS were rated ...
Known for Rgs2 Gene | Functional Polymorphism | Minor Allele | Association Rs4606
KOL-Index: 9450 . Comorbid schizophrenia and dementia is a common clinical phenomenon; however, management of the coexisting illnesses remains incomplete. Donepezil, a cholinesterase inhibitor, may be beneficial for the management of symptoms of Alzheimer's disease, a disease in which cholinergic pathways in the cerebral cortex and basal forebrain are well known to be compromised. Furthermore, impaired ...
Known for Donepezil Augmentation | Patients Schizophrenia | Comorbid Dementia | Cholinesterase Inhibitors
KOL-Index: 9275 . Electroconvulsive therapy (ECT) is an effective strategy in some treatment-resistant patients with schizophrenia. However, ECT is associated with cognitive adverse effects, most notably, memory loss. This study examined the effects of rivastigmine, a selective central nervous system acetylcholinesterase inhibitor, with benefits on cognition in Alzheimer disease, on memory performance in ...
Known for Electroconvulsive Therapy | Patients Schizophrenia | Memory Deficits | Ect Cognitive
KOL-Index: 9186 . Dehydroepiandrosterone (DHEA) and its sulfate derivative DHEA-S are neurosteroids, produced in the brain, and neuroactive steroids, produced in the adrenals and affecting the brain. We compared the ratios of serum cortisol/DHEA or DHEA-S in schizophrenia patients with normal subjects, and determined the correlation of these ratios with psychopathology and distress. Early morning plasma ...
Known for Schizophrenia Patients | Cortisol Dhea | Trait Anxiety | Dehydroepiandrosterone Ratio

Key People For Schizophrenia Patients

Top KOLs in the world
#1
Stanley R Kay
negative syndrome tardive dyskinesia pineal calcification
#2
Danniel R Weinberger,
prefrontal cortex patients schizophrenia magnetic resonance
#3
ABRAHAM Fiszbein
negative syndrome spanish adaptation psychotic disorders
#4
Robin MacGregor Murray
bipolar disorder episode psychosis obstetric complications
#5
Nancy C Andreasen
negative symptoms patients schizophrenia magnetic resonance
#6
Jeffrey A MD Lieberman
tardive dyskinesia weight gain episode schizophrenia

Mayanei Hayeshua Medical Center, HaRav Povarsky, 17, Bnei Brak, Israel | Psychiatry Department, Mayanei Hayeshua Medical Center, Bnei Brak, Israel | Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel | Department of Psychiatry, Tel Avi